Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Islet transplantation: need for a time-out?

Nature Clinical Practice Nephrology volume 4, pages 660–661 (2008)Cite this article

Insulin replacement therapy—in combination with diet and exercise—is the treatment of choice for patients with type 1 diabetes (T1D). The goal of this treatment is to normalize blood glucose levels throughout the day to prevent diabetic complications. Strategies include combined use of long-acting and short-acting preparations, and continuous insulin administration via a pump. Such intensive therapy can, however, cause hypoglycemic events, which are particularly dangerous in patients who do not experience the early warning signs of hypoglycemia.

Pancreatic islet β-cell transplantation has been proposed as an alternative treatment for patients with T1D. This approach has the theoretical advantages of a more physiological pattern of hormone release over insulin injection with a lower incidence of morbidity than whole-pancreas transplantation. However, less than 10% of the 267 islet transplantations attempted during the period 1990–2000 resulted in insulin independence for longer than 1 year.1 A turning point in islet transplantation was reached in 2000, when a steroid-free immunosuppressive regimen based on induction with daclizumab and maintenance therapy with sirolimus and low-dose tacrolimus—the so-called 'Edmonton protocol'—was tested. Insulin independence was maintained over a median follow-up of 1 year in all seven patients with T1D who were treated according to the Edmonton protocol after undergoing islet transplantation from two or three donor pancreases.1 This seminal experience prompted rapid expansion of islet cell transplantation programs worldwide.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Shapiro AM et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230–238

    Article  CAS  Google Scholar 

  2. Shapiro AM et al. (2006) International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355: 1318–1330

    Article  CAS  Google Scholar 

  3. Leichtman AB et al. (2008) Kidney and pancreas transplantation in the United States, 1997–2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 8: 946–957

    Article  CAS  Google Scholar 

  4. Johnston O et al. (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411–1418

    Article  Google Scholar 

  5. Nir T et al. (2007) Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117: 2553–2561

    Article  CAS  Google Scholar 

  6. Monti P et al. (2008) Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 118: 1806–1814

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Campbell PM et al. (2007) High risk of sensitization after failed islet transplantation. Am J Transplant 7: 2311–2317

    Article  CAS  Google Scholar 

  8. Olyaei AJ et al. (2001) Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7: 384–389

    Article  CAS  Google Scholar 

  9. Tomlanovich SJ and Vincenti F (2007) Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2: 198–199

    Article  CAS  Google Scholar 

  10. Senior PA et al. (2007) Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 7: 91–98

    Article  CAS  Google Scholar 

  11. Fioretto P et al. (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69–75

    Article  CAS  Google Scholar 

  12. Remuzzi G et al. (2002) Clinical practice: nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145–1151

    Article  Google Scholar 

  13. Haller MJ et al. (2007) Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr Opin Endocrinol Diabetes Obes 14: 283–287

    Article  Google Scholar 

  14. Hu CY et al. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117: 3857–3867

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. P Ruggenenti is Director of the Renal Medicine Department, A Remuzzi is Director of the Biomedical Engineering Department and G Remuzzi is Director of the Clinical Research Center for Rare Diseases “Aldo e Cele Daccò” at the Mario Negri Institute for Pharmacological Research, P Cravedi is a Clinical Researcher, Bergamo, Italy.,

    Paolo Cravedi, Piero Ruggenenti, Andrea Remuzzi & Giuseppe Remuzzi

  2. RB Mannon is Medical Director of Transplantation in the Transplantation Branch, NIDDK/NIH, Bethesda, MD, USA.,

    Roslyn B Mannon

Authors
  1. Paolo Cravedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roslyn B Mannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piero Ruggenenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Remuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Remuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Remuzzi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cravedi, P., Mannon, R., Ruggenenti, P. et al. Islet transplantation: need for a time-out?. Nat Rev Nephrol 4, 660–661 (2008). https://doi.org/10.1038/ncpneph0961

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0961

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing